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Theobromine, which is a caffeine derivative, is the primary methylxanthine produced by 50 
Theobroma cacao. Theobromine works as a phosphodiesterase (PDE) inhibitor to 51 
increase intracellular cyclic adenosine monophosphate (cAMP). cAMP activates the 52 
cAMP-response element-binding protein (CREB), which is involved in a large variety 53 
of brain processes, including the induction of the brain-derived neurotrophic factor 54 
(BDNF). BDNF supports cell survival and neuronal functions, including learning and 55 
memory. Thus, cAMP/CREB/BDNF pathways play an important role in learning and 56 
memory. Here, we investigated whether orally administered theobromine could act as a 57 
PDE inhibitor centrally and affect cAMP/CREB/BDNF pathways and learning behavior 58 
in mice.  59 
The mice were divided into two groups. The control group (CN) was fed a 60 
normal diet, whereas the theobromine group (TB) was fed a diet supplemented with 61 
0.05% theobromine for 30 days. We measured the levels of theobromine, 62 
phosphorylated vasodilator-stimulated phosphoprotein (p-VASP), phosphorylated 63 
CREB (p-CREB), and BDNF in the brain. p-VASP was used as an index of cAMP 64 
increases. Moreover, we analyzed the performance of the mice on a three-lever motor 65 
learning task. 66 
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Theobromine was detectable in the brains of TB mice. The brain levels of 67 
p-VASP, p-CREB, and BDNF were higher in the TB mice compared with those in the 68 
CN mice. In addition, the TB mice performed better on the three-lever task than the CN 69 
mice did. These results strongly suggested that orally administered theobromine acted as 70 
a PDE inhibitor in the brain, and it augmented the cAMP/CREB/BDNF pathways and 71 












1. Introduction 82 
In South America, chocolate has a long history dating back to at least 600 B.C. [1]. 83 
However, the first Westerner to eat chocolate is thought to be the 16th century Spanish 84 
general, Hernando Cortes [2]. Recently, consumption of chocolate with a high 85 
concentration of cacao (Theobroma cacao) has become popular around the world 86 
because cacao contains many flavonoids that have pleiotropic roles in neuroprotection 87 
and cognition [3, 4]. In addition, cacao contains theobromine, which is a caffeine 88 
derivative [5]. Theobromine is the primary methylxanthine found in products of 89 
Theobroma cacao [6]. Thus, an increase in chocolate intake results in an increase in the 90 
uptake of theobromine as well as flavonoids.  91 
Cyclic adenosine monophosphate (cAMP) is an intracellular second messenger 92 
that transduces extracellular signals into intracellular responses by communicating with 93 
downstream targets in the cascade [7]. cAMP signaling is fundamentally involved in 94 
neural wiring and the brain mechanisms that mediate cognitive processes [8-10]. 95 
Intracellular cAMP is synthesized from adenosine triphosphate by adenylyl cyclases and 96 
hydrolyzed by cyclic nucleotide phosphodiesterases (PDEs). cAMP activates the 97 
cAMP-response element-binding protein (CREB) through protein kinase A (PKA) 98 
activation [8-10]. The activation of CREB, which is a nuclear transcription factor, is 99 
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involved in a large variety of brain processes, including the induction of brain-derived 100 
neurotrophic factor (BDNF) [11]. BDNF supports cell survival and neuronal functions, 101 
including the neuroplasticity that mediates learning and memory [11]. Thus, the 102 
cAMP/CREB/BDNF pathways play important roles in cognitive processes, including 103 
learning and memory. Consequently, there has been significant interest in targeting 104 
PDEs as cognition-enhancing drugs [12-14].  105 
Methylxanthines, including theobromine, are well-known inhibitors of PDEs 106 
[15-18]. We have previously confirmed that theobromine increases the intracellular 107 
cAMP concentration in glioblastomas [19]. Thus, theobromine might enhance cognitive 108 
function through cAMP/CREB/BDNF pathways. However, the in vivo physiological 109 
and pharmacological actions of theobromine have not been fully elucidated. In this 110 
study, we examined whether orally administered theobromine enhanced the 111 
cAMP/CREB/BDNF pathways and/or cognitive function by conducting the following 112 
experiments in theobromine-fed mice. First, we measured the theobromine 113 
concentrations in the plasma and cerebral cortex. Second, we analyzed the levels of the 114 
vasodilator-stimulated phosphoprotein (VASP) in the cerebral cortex. VASP is an 115 
established substrate for PKA, and its phosphorylation reflects PKA activation 116 
following an increase in cAMP [20-22]. Third, we analyzed the activation of CREB in 117 
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the cerebral cortex and hippocampus. Fourth, we measured the BDNF levels in the 118 
cerebral cortex and hippocampus. Finally, we analyzed the performance of the mice on 119 
a three-lever operant task that was developed to study several different aspects of motor 120 
learning, including sequence learning, skill learning, adaptation, and reversal learning, 121 
in mice [23]. We found that the theobromine-fed mice performed better on the 122 
three-lever motor learning task. In addition, the cAMP/CREB/BDNF pathways were 123 
enhanced in these mice.  124 
 125 
 126 
2. Materials and Methods 127 
2.1 Animals 128 
Male C57BL/6NCr mice were purchased from Japan SLC, Inc. (Hamamatsu, Japan) 129 
and housed in a room with controlled temperature (23 ± 2°C) and humidity (50 ± 10%) 130 
and under a 12/12 h light–dark cycle. They had access to food and water ad libitum. At 131 
the end of the experiments, the mice were sacrificed with an overdose of isoflurane. All 132 
animal experiments were performed in accordance with the Guidelines for Animal 133 
Experimentation of Shimane University Faculty of Medicine and the animal welfare 134 
committee of Kanazawa University, which complied with the Guidelines for Animal 135 
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Experimentation of the Japanese Association for Laboratory Animal Science. 136 
 137 
2.2 Materials 138 
Theobromine, caffeine-d9, and the Glucose CII-Test WAKO Kit were purchased from 139 
Wako Pure Chemical Industries, Ltd. (Osaka, Japan). The BDNF Emax® ImmunoAssay 140 
System was purchased from Promega Corporation (Madison, WI, USA). 141 
Anti-phospho-VASP (Ser239), anti-βactin, anti-CREB, anti-phospho-CREB (Ser133), 142 
horseradish peroxidase (HRP)-linked anti-mouse IgG, and anti-rabbit IgG antibodies 143 
were purchased from Cell Signaling Technology, Inc. (Danvers, MA, USA). 144 
 145 
2.3 Feeding and experiment schedules 146 
The feeding and experiment schedules are summarized in Figure 1. All of the mice had 147 
free access to a standard chow (CRF-1, Oriental Yeast Co., LTD., Tokyo, Japan) for 148 
several days after admission. On Day0, the mice were divided into two groups. The first 149 
group, which consisted of the control (CN) mice, was fed the CRF-1 chow for 30 days 150 
and then subsequently switched to the CE-2 chow (O'HARA & Co., Ltd., Tokyo, Japan) 151 
for the remaining 30 days. The second group of mice (TB) was fed the standard CRF-1 152 
chow that was supplemented with 0.05% (W/W) of theobromine (Oriental Yeast Co., 153 
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LTD.) for 30 days and then switched to the CE-2 chow for the remaining 30 days. 154 
During the period of operant task performance (Day30 to Day60), the CE-2 chow (50 155 
mg/1 pellet) was used instead of the CRF-1 chow (3–4 g/1 pellet) to adjust for the total 156 
amount of food per day (1.5–2.5 g). 157 
The concentration of theobromine (0.05%) was selected according to the 158 
caffeine-supplemented chow [24] because theobromine is a caffeine derivative. The 159 
length of time for treatment (30 days) was selected based on our preliminary data with 160 
rats that showed the theobromine concentration in the plasma gradually increased and 161 
reached submaximal levels 30 days after switching to the theobromine-supplemented 162 
chow (unpublished preliminary data). 163 
The body weights of the mice were measured at the beginning (Day0; start of 164 
theobromine feeding), halfway point (Day30; switching to CE-2 chow), and end 165 
(Day60; finish) of the experiments. The theobromine concentrations in the plasma and 166 
cerebral cortex were measured at the halfway point (Day30) and on the final (Day60) 167 
day of the experiments. The levels of plasma glucose, phosphorylated VASP, CREB, 168 
and BDNF were measured at the halfway (Day30) point of the experiments. The lever 169 
operant tasks were performed for a 30-d period from the halfway point (Day30) until the 170 




2.4 Measurements of plasma glucose 173 
The plasma glucose concentrations were determined with a Glucose CII-Test WAKO 174 
Kit (Wako Pure Chemical Industries, Ltd.) according to the kit’s instructions. 175 
 176 
2.5 Measurements of theobromine content 177 
Theobromine was measured in the biological samples as previously described, with a 178 
slight modification [25]. The brain tissues were homogenized in four volumes (w/v) of 179 
phosphate-buffered saline (pH 7.4). We mixed 50 µL of plasma and brain homogenate 180 
with 250 ng of caffeine-d9 in 200 μL of acetonitrile and then kept the samples at -30°C 181 
for 30 min. The samples were centrifuged at 5,000 × g for 10 min at 4°C to remove the 182 
precipitated proteins. The supernatants were analyzed with high-performance liquid 183 
chromatography in combination with electrospray ionization-mass spectrometry that 184 
was performed with a TSQ quantum mass spectrometer (Thermo Fisher Scientific K.K., 185 
Tokyo, Japan). The high-performance liquid chromatography was performed with a 186 
Luna 3-μm C18(2) 100Å liquid chromatography column (100 × 2.0 mm, Phenomenex, 187 
Inc., Torrance, CA, USA) at 30°C. The samples were eluted in a mobile phase 188 
consisting of acetonitrile–methanol (4:1, v/v) and water–acetic acid (100:0.1, v/v) in a 189 
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10:90 ratio for 2 min. After 5 min, the ratio was changed to 70:30 and maintained for 7 190 
min. Subsequently, the ratio was changed to 80:20 and held for 2 min. Finally, after 9 191 
min, the ratio was changed to 100:0 and held for 2 min with a flow rate of 0.1 mL/min. 192 
Tandem mass spectrometry analyses were conducted in the positive ion mode, and 193 
theobromine (m/z 180.8>163.1) and caffeine-d9 (m/z 204.2>144) were detected and 194 
quantified with selected reaction monitoring. The peaks were selected, and their areas 195 
were calculated with Xcalibur™ 2.1 software (Thermo Fisher Scientific K.K.). 196 
 197 
2.6 Levels of BDNF, phosphorylated VASP, and CREB  198 
The cerebral cortex and hippocampus were homogenized in radioimmunopreciptation 199 
assay buffer with a glass homogenizer. Subsequently, the samples were centrifuged at 200 
800 × g for 15 min at 4°C to remove tissue debris, and a protein assay was performed to 201 
determine the protein concentrations. Equal amounts of protein were analyzed with the 202 
BDNF Emax® ImmunoAssay System (Promega Corporation) according to the kit’s 203 
instructions. Western blotting was performed as previously described [26]. The proteins 204 
in the cerebral cortex and hippocampus were separated with 10% sodium dodecyl 205 
sulfate-polyacrylamide gel electrophoresis. The resolved proteins were transferred onto 206 
polyvinylidene fluoride membranes and incubated with primary antibodies (1:1,000) 207 
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and then HRP-linked secondary antibodies (1:2,000). The blots were developed with the 208 
Immobilon Western Chemiluminescent HRP Substrate (EMD Millipore Corporation, 209 
Billerica, MA, USA). 210 
 211 
2.7 One-lever and three-lever operant tasks 212 
The one-lever and three-lever operant tasks were performed as previously described 213 
[23]. Ten CN mice and 10 TB mice that were 6 weeks old on Day0 were kept separately 214 
in plastic cages with four compartments (KN-606, 230 × 300 × 130 mm, Natsume 215 
Seisakusho Co., Ltd., Tokyo, Japan) and provided a limited amount of food. Before the 216 
training, the mice were handled for approximately 10 min/day for one week in order for 217 
the mice to habituate to the testing area and experimenter. One 60-min training session 218 
was conducted once a day five days a week (Monday to Friday). The experiments were 219 
performed in an operant chamber (225 × 240 × 200 mm, OP-3101K, O'HARA & Co., 220 
Ltd.) that was placed in a sound-attenuating box (495 × 750 × 685 mm). Three levers 221 
(18 × 15 mm) protruded into the chamber, and the right (A), center (B), and left (C) 222 
levers were positioned 2, 4, and 2 cm, respectively, above the floor. The B-lever was set 223 
2 cm higher than the other two levers so that the mouse pressed the B-lever with a 224 
forelimb by standing up on its hind legs. The Operant Task for multi levers program 225 
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(O'HARA & Co., Ltd.) controlled the execution of all experiments and data collection. 226 
When the mouse pressed an active lever (one-lever task) or three levers in the correct 227 
order within a given time (three-lever task), one pellet (AIN-76A, 10 mg, Research 228 
Diets, Inc., New Brunswick, NJ, USA) was delivered from the automatic diet feeder for 229 
reinforcement (PD-010D, O'HARA & Co., Ltd). The required load for the lever press 230 
was adjusted to 4–7 g. The number of reinforcements (R, pellets) and presses on each 231 
lever were recorded on a personal computer through an interface unit (AOI040C, 232 
O'HARA & Co., Ltd.) by the task program. In the operant chamber, water was available 233 
ad libitum. 234 
The one-lever task was used as a shaping procedure for the three-lever task. In 235 
this task, the mouse was trained to press any one of the active levers for a food reward 236 
(fixed ratio 1, FR1). The number of active levers was initially set to three. When the 237 
mouse pressed the same active lever more than 100 times per session in two consecutive 238 
sessions, the lever was inactivated in the subsequent sessions. The one-lever task was 239 
completed when the mouse pressed the last active lever more than 100 times per session 240 
in two consecutive sessions.  241 
The mouse was then trained to press the three levers in an ABC sequence 242 
(A-lever, B-lever, and C-lever). In this three-lever task, the mouse was required to press 243 
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the second (or third) lever within a given time (T) after the onset of the first (or second) 244 
lever press. Initially, T was set to 99.9 s, and it was sequentially decreased to 3 s, 2 s, 245 
and 1 s when R was over 100 in two consecutive sessions. After completion of the 246 
three-lever task, the mouse was trained to press the three levers in the opposite sequence 247 
(CBA; C-lever, B-lever, and A-lever). Like the original three-lever task, T was initially 248 
set to 99.9 s, and it was sequentially decreased to 3 s, 2 s, and 1 s when R was over 100 249 
in two consecutive sessions. 250 
 251 
2.8 Statistical analysis 252 
The data are expressed as mean ± standard error of the mean. Statistical significance 253 
was evaluated with a two-way analysis of variance (ANOVA) or Student’s t-test. P 254 
values less than 0.05 were considered statistically significant. The p value, effect size 255 
(d), and power (1-β) were obtained with Statcel software.  256 
 257 
 258 
3. Results 259 
3.1 Body weights and plasma glucose levels 260 
First, we measured the body weights and plasma glucose levels. The body weights of 261 
16 
 
the mice fed the theobromine-supplemented chow (TB mice, n = 10) did not differ from 262 
those of the mice fed the standard chow (CN mice, n = 10) on Day0 (p = 0.15), Day30 263 
(p = 0.59), or Day60 (p = 0.57) (Table 1). The plasma glucose levels of the TB mice (n 264 
= 6) did not differ from those of the CN mice (n = 6) on Day30 (p = 0.52; Table 2). 265 
These results indicated that theobromine did not affect the feeding behavior or glucose 266 
metabolism of the mice. 267 
 268 
3.2 Theobromine concentrations in the plasma and brain 269 
Next, we examined whether theobromine was taken up into the brain. In the CN mice (n 270 
= 6), theobromine was not detected in the plasma or cerebral cortex on Day30 or Day60 271 
(Table 2). In the TB mice (n = 6), the theobromine concentrations in the plasma and 272 
cerebral cortex were 2.20 ± 0.12 μg/mL and 0.21 ± 0.02 μg/mL, respectively, on Day30 273 
(Table 2). However, theobromine was no longer detected in the plasma and cerebral 274 
cortex 30 days after the theobromine-supplemented chow was replaced with the 275 
standard chow (Day 60; Table 2). The presence of theobromine in the brains of the TB 276 
mice indicated that orally administered theobromine influenced the signaling pathways 277 




3.3 Levels of phosphorylated VASP, phosphorylated CREB, and BDNF in the brain 280 
Next, we examined whether orally administered theobromine enhanced the 281 
cAMP/CREB/BDNF pathway in the brain in the CN mice (n = 6) and TB mice (n = 6) 282 
on Day30. The levels of phosphorylated VASP protein in the cerebral cortex were 283 
significantly higher in the TB mice than in the CN mice (p < 0.05) (Fig. 2), which 284 
indicated that the TB mice had increased levels of intracerebral cAMP. The levels of 285 
phosphorylated CREB in both the hippocampus and cerebral cortex were significantly 286 
higher in the TB mice than in the CN mice (p < 0.05; Fig. 3). The protein expression 287 
levels of BDNF in the hippocampus and cerebral cortex were also significantly higher 288 
in the TB mice than in the CN mice (p < 0.01 and p < 0.05, respectively; Table 2). These 289 
results indicated that orally administered theobromine activated the 290 
cAMP/CREB/BDNF pathways in the brain. 291 
 292 
3.4 One-lever and three-lever operant tasks 293 
Finally, we analyzed the performances of the CN mice (n = 10) and TB mice (n = 10) on 294 
the three-lever operant task. The CN mice and TB mice generally exhibited similar 295 
performances on the one-lever task (Fig. 4), which was used as a shaping procedure for 296 
the three-lever task. The total number of sessions required to complete the one-lever 297 
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task was 10.3 ± 0.7 sessions in the CN mice and 10.3 ± 0.3 sessions in the TB mice (Fig. 298 
4B), which was not a significant difference (p = 0.99). In the first several sessions, both 299 
types of mice exhibited similar increases in the total number of lever presses (Fig. 4A). 300 
A two-way ANOVA (session × mouse group) showed no significant interaction effects 301 
of session and mouse group (p = 0.88) and a significant main effect of session (p < 302 
0.001) but not mouse group (p = 0.23).  303 
In the three-lever task, the TB mice exhibited a significantly better performance 304 
than the CN mice did (Fig. 5). In the first several sessions, the total number of lever 305 
presses (Fig. 5A) exhibited a significant interaction effect of session and mouse group 306 
(p < 0.01). In addition, the total number of presses was significantly higher in the TB 307 
mice than in the CN mice in the first session (p < 0.05) but not in the subsequent 308 
sessions (p > 0.05). The number of reinforcements, success rates, and number of lever 309 
presses for the ABCABC pattern were significantly increased in the TB mice than in the 310 
control mice (Fig. 5B-D). A two-way ANOVA showed no significant interaction effects 311 
of session and mouse group (reinforcement, p = 0.35; success rate, p = 0.83; ABCABC, 312 
p = 0.09) and significant main effects of session (reinforcement, success rate, and 313 
ABCABC, p < 0.001) and mouse group (reinforcement, p < 0.01, d = 0.28, 1 - β = 0.79; 314 
success rate, p < 0.001, d = 0.45, 1 - β = 0.99; ABCABC, p < 0.01, d = 0.35, 1 - β = 315 
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0.94). The total number of sessions required to complete the three-lever task differed 316 
significantly between the CN and TB mice (CN mice, 9.6 ± 0.4 sessions; TB mice, 8.3 ± 317 
0.1 sessions; p < 0.05). These results demonstrated that the TB mice performed 318 
significantly better on the three-lever operant task compared with the CN mice. 319 
 Better performances of the TB mice were also observed on the reverse 320 
three-lever task (CBACBA), although the differences in the performances between the 321 
two groups were less obvious. The total numbers of sessions required to complete the 322 
reverse three-lever task were similar (CN mice, 8.4 ± 0.2 sessions; TB mice, 8.3 ± 0.2 323 
sessions; p = 0.45). The total number of lever presses (Fig. 6A) exhibited no significant 324 
interaction effects of session and mouse group (p = 0.59) and significant main effects of 325 
both session (p < 0.001) and mouse group (p < 0.05, d = 0.23, 1 - β = 0.63). The number 326 
of reinforcements and success rates showed no significant interaction effects of session 327 
and mouse group (reinforcement, p = 0.79; success rate, p = 0.83) and a significant main 328 
effect of session (reinforcement and success rate, p < 0.001) but not mouse group 329 
(reinforcement, p = 0.75, d = 0.03, 1 - β = 0.06; success rate, p = 0.06, d = 0.20, 1 - β = 330 
0.51). Importantly, the number of lever presses for the CBACBA pattern (Fig. 6D) was 331 
significantly increased in the TB mice compared with the CN mice. Session and mouse 332 
group did not exhibit a significant interaction effect (p = 0.70), while they did show 333 
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significant main effects (session, p < 0.001; mouse group, p < 0.05, d = 0.26, 1 - β = 334 
0.73).  335 
 336 
 337 
4. Discussion 338 
Several lines of evidence have shown that theobromine exerts a variety of physiological 339 
and pharmacological actions [6, 27, 28]. Notably, theobromine functions as an inhibitor 340 
of PDEs, including PDE4 [19], which results in an increase in intracellular cAMP. 341 
PDE4 inhibitors prevent cognitive deficits. Therefore, theobromine might serve as a 342 
potential protective agent against cognitive disorders [13, 14]. This possibility was 343 
supported by the results of the present study, which demonstrated that orally 344 
administered theobromine influenced signaling pathways in the brain, including those 345 
for cAMP, CREB, and BDNF, and facilitated motor learning in mice. 346 
In order to exert its effect against cognitive disorders, theobromine must be 347 
taken up into the brain. Our data showed that theobromine was detectable in the plasma 348 
and cerebral cortex of the mice 30 days after initiation of the theobromine-supplemented 349 
chow. The plasma and brain levels of theobromine were about 2.2 and 0.2 μg/mL, 350 
respectively. The level of 0.2 μg/mL is sufficient to produce pharmacological effects 351 
21 
 
[29]. However, the concentrations differed greatly between the plasma and brain. The 352 
molecular structure of theobromine is very similar to that of caffeine. Caffeine freely 353 
crosses the blood-brain barrier (BBB), and its concentration in the brain is almost the 354 
same as it is in plasma [30-32]. Thus, the permeability of the BBB to theobromine 355 
would be much lower than that to caffeine. 356 
Isoflurane, which was used as an anesthetic agent in the present study, is 357 
thought to have effects on the permeability of the BBB [33, 34]. Therefore, we cannot 358 
exclude the possibility that our biochemical data might have been affected by alterations 359 
in the BBB that were induced by isoflurane. The BBB selectively controls the 360 
homeostasis of the central nervous system environment through specific structural and 361 
biochemical features of endothelial cells, pericytes, and glial cells [35]. In addition, tight 362 
junction molecules between the brain endothelial cells contain the molecular 363 
components of the BBB [33]. Alterations to the cellular and molecular structures may 364 
result in BBB disruption. Isoflurane inhibits the expression of occludin, which is a tight 365 
junction molecule, and influences BBB integrity [34]. However, the downregulation of 366 
occludin takes time, and a 1-h exposure to isoflurane in vivo does not alter the 367 
morphology of the BBB visualized with electron microscopy [36]. In the present study, 368 
the exposure to isoflurane was only a few minutes. Thus, the BBBs of the mice used in 369 
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the present study were assumed to be relatively intact.     370 
The present study demonstrated that orally administered theobromine enhanced 371 
the cAMP/CREB/BDNF pathways in the brain and motor learning. Theobromine, which 372 
is a well-known inhibitor of PDEs [19], was expected to increase the concentration of 373 
cAMP by preventing the hydrolysis of cAMP. We showed that the levels of 374 
phosphorylated VASP protein in the cerebral cortex were significantly higher in the TB 375 
mice compared with the CN mice (Fig. 2). Because VASP is an established substrate of 376 
PKA, increased levels of phosphorylated VASP indicated increased cAMP and the 377 
resulting PKA activation [20-22]. Therefore, our data strongly suggested that orally 378 
administered theobromine acted as a PDE inhibitor and increased the cAMP levels in 379 
the brain. cAMP plays an important role in various neural functions [7, 37, 38] as a 380 
second messenger molecule. In particular, cAMP signaling is involved in synaptic 381 
plasticity, such as long-term potentiation [8, 9, 39-41], which is crucial for learning and 382 
memory [8, 9]. Furthermore, cAMP is known to activate CREB through PKA activation 383 
[8, 9]. In addition, CREB has been implicated in long-term potentiation and the 384 
production of BDNF. BDNF is one of several neurotrophins that regulate synaptic 385 
plasticity [8, 9, 39-41]. Thus, the cAMP/CREB/BDNF pathways are heavily involved in 386 
learning and memory. In the present study, we observed that the levels of 387 
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phosphorylated CREB and BDNF, as well as phosphorylated VASP, were increased in 388 
the brains of TB mice when they were measured 30 days after the start of the 389 
theobromine-supplemented chow (Table 2 and Fig. 3). These results indicated that 390 
orally administered theobromine facilitated the cAMP/CREB/BDNF pathways in the 391 
brain. More importantly, we observed that orally administered theobromine enhanced 392 
motor learning (Figs. 5 and 6). Our observations were in agreement with previous 393 
findings concerning the roles of the cAMP/CREB/BDNF pathways in learning and 394 
memory. 395 
Lastly, the question remains as to how long the effects of theobromine on the 396 
brain signaling pathways and functions last. Theobromine was not detectable in the 397 
plasma and brains of the mice in the TB group 30 days after replacement (Day60) of the 398 
theobromine-supplemented chow with the standard chow. However, the 399 
theobromine-mediated enhancement of motor learning was observed between Day30 400 
and Day60. When the theobromine disappears in the plasma and brain after the 401 
theobromine chow is stopped is unclear. 402 
 403 
 404 
5. Conclusions 405 
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This study demonstrated that orally administered theobromine acted as a PDE inhibitor 406 
in the brain, influenced the signaling pathways, including those for cAMP, CREB and 407 
BDNF, and facilitated motor learning in mice. We confirmed that theobromine was 408 
present in the brains of the theobromine-fed mice and that it increased the cAMP levels. 409 
cAMP signaling mediates numerous neural processes, including development, cellular 410 
excitability, synaptic plasticity, learning, and memory. Increased cAMP phosphorylates 411 
CREB and, in turn, releases BDNF. The cAMP, CREB, and BDNF pathways mediate 412 
synaptic plasticity, thus facilitating behavioral learning and memory. Therefore, our 413 
findings strongly suggested that cacao products, including chocolate and cocoa, can 414 
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Table 1 569 
 570 
Body Weights [g, mean ± standard error of the mean (SEM)] in control (CN) and 571 
theobromine-fed (TB) mice 572 
 573 
    CN (n = 10)  TB (n = 10) P value 574 
Initial 575 
(Day0)    21.1 ± 0.4  21.9 ± 0.3 P = 0.15 576 
Halfway 577 
(Day30)    24.6 ± 0.4  24.3 ± 0.4  P = 0.59 578 
Final 579 
(Day60)    24.9 ± 0.5  24.5 ± 0.3  P = 0.57 580 
 581 
  582 
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Table 2 583 
 584 
Glucose levels in plasma, theobromine levels in plasma and the cerebral cortex, and 585 
brain-derived neurotrophic factor (BDNF) levels in the hippocampus and cerebral 586 
cortex in control (CN) and theobromine-fed (TB) mice 587 
 588 
        CN (n = 6) TB (n = 6)     P value 589 
 590 
Glucose (Day30) 591 
(mg/dL plasma)  254.6 ± 13.85 241.35 ± 12.91      P = 0.52 592 
 593 
 594 
Theobromine (Day30) 595 
(μg/mL plasma)  Not detected 2.20 ± 0.12  596 
(μg/mL cerebral cortex) Not detected 0.21 ± 0.02   597 
 598 
Theobromine (Day60) 599 
(μg/mL plasma)  Not detected Not detected  600 
36 
 
(μg/mL cerebral cortex) Not detected Not detected  601 
 602 
 603 
BDNF (Day30) 604 
(pg/g hippocampus)  25.81 ± 0.85 29.60 ± 0.99      P = 0.0086 605 
(pg/g cerebral cortex) 20.28 ± 0.61 22.67 ± 0.82      P = 0.029 606 
 607 
 608 
Each value represents the mean ± SEM 609 
 610 
  611 
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Figure legends 612 
Figure 1 613 
Feeding and experiment schedules. The mice were divided into two groups. The mice in 614 
the first group (control; CN) were fed the standard chow (CRF-1) for 30 days and were 615 
then switched to CE-2 for 30 days. The second group (theobromine; TB) was fed chow 616 
supplemented with 0.05% (W/W) theobromine (CRF-1 with 0.05% of theobromine) for 617 
30 days and were then switched to CE-2 for 30 days. Body weight was measured on 618 
Day0, Day30, and Day60. The theobromine concentrations in plasma and the cerebral 619 
cortex were measured on Day30 and Day60. The plasma glucose, brain-derived 620 
neurotrophic factor (BDNF), phosphorylated vasodilator-stimulated phosphoprotein 621 
(VASP), and cAMP-response element-binding protein (CREB) levels were measured on 622 
Day30. The Lever operant tasks were performed between Day30 and Day60. 623 
 624 
Figure 2 625 
Phosphorylated VASP levels in the cerebral cortex of the mice. Theobromine induces 626 
VASP phosphorylation in the cerebral cortex of mice. Each data point represents the 627 




Figure 3 630 
Phosphorylated CREB levels in the hippocampus and cerebral cortex of mice. 631 
Theobromine induces CREB phosphorylation in the hippocampus and cerebral cortex of 632 
the mice. Each data point represents the mean ± SEM (n = 6, ∗P < 0.05). 633 
 634 
Figure 4 635 
Performance on the one-lever task. The time course of the total number of lever presses 636 
during the 1st–8th sessions (A) and the number of sessions required for the completion 637 
of the one-lever task (B). Each data point represents the mean ± SEM (n = 10). 638 
Statistical significance was evaluated with a two-way analysis of variance (ANOVA; A) 639 
or Student’s t-test (B). 640 
 641 
Figure 5 642 
Performance on the three-lever task. The time courses of the total number of lever 643 
presses (A), number of reinforcements (B), success rates (C), and number of lever 644 
presses for the A→B→C→A→B→C (ABCABC) pattern (D) during the 1st–5th 645 
sessions. Each data point represents the mean ± SEM (n = 10). Statistical significance 646 
was evaluated with a two-way ANOVA. Differences with P values less than 0.05 were 647 
39 
 
considered significant. 648 
 649 
Figure 6 650 
Performance on the reverse three-lever task. The time courses of the total number of 651 
lever presses (A), number of reinforcements (B), success rates (C), and number of lever 652 
presses for the C→B→A→C→B→A (CBACBA) pattern (D) during the 1st–5th 653 
sessions. Each data point represents the mean ± SEM (n = 10). Statistical significance 654 
was evaluated with a two-way ANOVA. Differences with P values less than 0.05 were 655 
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